clinical trial · NCT07493122
Study of IMC-S118AI in Type 1 Diabetes
Type 1 DiabetesType 1 Diabetes (T1D)Diabetes Type 1IMC-S118AI
brief summary
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
started
Apr 1, 2026
primary completion
Nov 1, 2030
completion
Nov 1, 2030
last updated
Mar 25, 2026
official title
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol